<DOC>
	<DOCNO>NCT01984606</DOCNO>
	<brief_summary>The purpose study assess safety efficacy empagliflozin compare sitagliptin patient type 2 diabetes mellitus treatment-naive treatment metformin insufficient glycaemic control . The study assess non-inferiority empagliflozin sitagliptin regard HbA1c .</brief_summary>
	<brief_title>Efficacy Safety Empagliflozin Versus Sitagliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion : Inclusion criterion : Diagnosis type 2 diabetes mellitus . Male female patient diet exercise regimen : Treatmentnaïve , define absence oral antidiabetic therapy 12 week prior randomisation . Pretreated immediate release metformin unchanged 10 week prior randomisation . Minimum dose metformin : &gt; =1500 mg/day maximum tolerate dose maximum dose accord local label . HbA1c &gt; = 7.5 % &lt; = 10.5 % Visit 1 3 . Age &gt; = 18 yr . Exclusion criterion : Uncontrolled hyperglycaemia glucose level &gt; 270 mg/dL ( &gt; 15 mmol/L ) overnight fast dose stabilisation ( applicable ) and/or placebo runin . Any antidiabetic drug within 12 week prior randomisation ( applicable treatmentnaïve patient ) . Any antidiabetic drug within 10 week prior randomisation except metformin ( applicable patient background treatment metformin ) . Acute coronary syndrome ( nonSTEMI , STEMI unstable angina pectoris ) , stroke TIA within 3 month prior inform consent . Indication liver disease . Moderate severe renal impairment . Bariatric surgery within past two year . Treatment antiobesity drug 3 month prior inform consent . Current treatment systemic steroid time inform consent uncontrolled endocrine disorder except type 2 diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>